The Cryptosporidium Parvum Kinome.
Artz, J.D., Wernimont, A.K., Allali-Hassani, A., Zhao, Y., Amani, M., Lin, Y.H., Senisterra, G., Wasney, G.A., Fedorov, O., King, O., Roos, A.K., Lunin, V.V., Qiu, W., Finerty, P.J., Hutchinson, A., Chau, I., von Delft, F., MacKenzie, F.I., Lew, J., Kozieradzki, I., Vedadi, M., Schapira, M., Zhang, C., Shokat, K.M., Heightman, T., Hui, R.(2011) BMC Genomics 12: 478
- PubMed: 21962082 
- DOI: https://doi.org/10.1186/1471-2164-12-478
- Primary Citation of Related Structures:  
2WEI - PubMed Abstract: 
Hundreds of millions of people are infected with cryptosporidiosis annually, with immunocompromised individuals suffering debilitating symptoms and children in socioeconomically challenged regions at risk of repeated infections. There is currently no effective drug available. In order to facilitate the pursuit of anti-cryptosporidiosis targets and compounds, our study spans the classification of the Cryptosporidium parvum kinome and the structural and biochemical characterization of representatives from the CDPK family and a MAP kinase.
Organizational Affiliation: 
Structural Genomics Consortium, University of Toronto, MaRS South Tower, Floor 7, 101 College St, Toronto, Ontario M5G 1L7, Canada. jdartz@gmail.com